FDA Clears Actemra Biosimilar Tofidence
Developed by Bio-Thera Solutions, treatment is indicated for patients with three different types of arthritis.
Bio-Thera Solutions, Ltd revealed that it has received FDA approval for Tofidence (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing Actemra. The treatment is approved for the treatment of patients with moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis.
Bio-Thera and Biogen entered a partnership to develop Tofidence in April 2021.
"The approval of TOFIDENCE is a landmark achievement for Bio-Thera as it marks Bio-Thera's first FDA approval for a product in the United States" said Shengfeng Li, CEO, Bio-Thera. "Bio-Thera is committed to developing biosimilars for patients around the globe and this approval demonstrates that commitment."
Reference: FDA Approves TOFIDENCE™ (tocilizumab-bavi) a Biosimilar of ACTEMRA® developed by Bio-Thera Solutions. PR Newswire. October 8, 2023. Accessed October 9, 2023. https://www.prnewswire.com/news-releases/fda-approves-tofidence-tocilizumab-bavi-a-biosimilar-of-actemra-developed-by-bio-thera-solutions-301950199.html
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
